Takara Bio Inc

Takara Bio (4974 JP): FY23 Looks Uncertain as COVID-19 PCR Testing Number Decline Is Inevitable

Equity Bottom-Up
228 Views, 04 May 2022 18:38
EXECUTIVE SUMMARY
  • Takara Bio Inc (4974 JP) reported 55% y/y growth in revenue during the first nine months of FY22, mainly driven by 129% y/y surge in COVID-19 PCR test reagent revenue.
  • Although Takara Bio is likely to beat its FY22 guidance, uncertainty is prevailing for revenue earning potential beyond FY22, when the COVID-19 test demand will fade away.  
  • We would stay away from this idea for now and wait on the sideline for a clarity of growth potential and recovery in the base business in FY23 and beyond. 
detail (4-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare compa... 

Zoom:
NaN%
x